List of Excipients in Branded Drug LIPITOR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Parke-Davis Div of Pfizer Inc	LIPITOR	atorvastatin calcium	0071-0155	CALCIUM CARBONATE
Parke-Davis Div of Pfizer Inc	LIPITOR	atorvastatin calcium	0071-0155	CANDELILLA WAX
Parke-Davis Div of Pfizer Inc	LIPITOR	atorvastatin calcium	0071-0155	CELLULOSE, MICROCRYSTALLINE
Parke-Davis Div of Pfizer Inc	LIPITOR	atorvastatin calcium	0071-0155	CROSCARMELLOSE SODIUM

LIPITOR Excipient Strategy, Formulation Patents, Generic Entry, and Commercial Opportunities

Last updated: September 24, 2026

LIPITOR is the brand name for atorvastatin calcium, a small-molecule HMG-CoA reductase inhibitor originally developed and marketed by Warner-Lambert and later Pfizer. Its commercial exclusivity has ended, and generic atorvastatin is widely available in the United States. The current commercial opportunity is therefore not protection of the original atorvastatin molecule. It is differentiation through excipient performance, dosage-form innovation, manufacturing efficiency, regulatory strategy, and access to markets where branded or differentiated atorvastatin products retain value.

LIPITOR tablets use a conventional immediate-release solid oral formulation. The principal excipient opportunity lies in developing improved versions of atorvastatin calcium rather than duplicating the original formulation.

What is LIPITOR and what formulation does it use?

LIPITOR contains atorvastatin calcium, equivalent to 10 mg, 20 mg, 40 mg, or 80 mg of atorvastatin. The product is an immediate-release, film-coated tablet administered orally for hypercholesterolemia and prevention of cardiovascular events.

The U.S. prescribing information identifies the following inactive ingredients:

Formulation component	Function in the product
Calcium carbonate	Alkalinizing agent and filler
Candelilla wax	Tablet coating and polishing aid
Cellulose	Binder or filler
Croscarmellose sodium	Superdisintegrant
Hypromellose	Film-forming coating polymer
Lactose monohydrate	Diluent
Magnesium stearate	Lubricant
Microcrystalline cellulose	Diluent and compression aid
Polysorbate 80	Surfactant
Talc	Glidant and coating component
Titanium dioxide	Opacifying pigment

The formulation is designed for conventional tablet manufacture, coating, rapid disintegration, and oral absorption. The presence of calcium carbonate, polysorbate 80, and a disintegrant system reflects the need to manage atorvastatin calcium’s formulation properties and dissolution behavior. [1]

What excipients are protected by the original LIPITOR patents?

The original LIPITOR estate was primarily directed to atorvastatin, atorvastatin calcium, crystalline forms, pharmaceutical compositions, and therapeutic uses. The commercial barriers were not based solely on the tablet’s inactive ingredients.

The most commercially important original U.S. patents included:

Patent	General subject matter	Commercial relevance
U.S. Patent No. 4,681,893	Atorvastatin compounds and related statin chemistry	Core compound protection
U.S. Patent No. 5,273,995	Atorvastatin calcium and related compositions	Salt and pharmaceutical product protection
U.S. Patent No. 5,969,156	Atorvastatin calcium forms and composition-related claims	Supplementary product protection

Patent scope and expiration depended on claim construction, terminal disclaimers, patent-term adjustments, pediatric extensions, and settlement agreements. The core U.S. atorvastatin patent barriers expired before or during the early 2010s, allowing generic atorvastatin entry. The relevant commercial milestone was November 30, 2011, when Ranbaxy began generic atorvastatin supply under its settlement with Pfizer. [2,3]

The original LIPITOR inactive-ingredient combination should not be treated as a current blocking patent position without a claim-by-claim review of issued patents, continuations, terminal disclaimers, and jurisdiction-specific status. The practical market position is that the basic immediate-release atorvastatin tablet is open to generic competition.

When did LIPITOR lose exclusivity?

LIPITOR lost effective U.S. market exclusivity in stages.

Milestone	Date or period	Commercial effect
FDA approval of LIPITOR	December 17, 1996	Launch of branded atorvastatin
Peak commercial period	2000s to early 2010s	Global blockbuster sales
Core patent expiry period	Mid-2000s, subject to extensions and litigation	Reduction in compound-level protection
Authorized-generic and settlement activity	2011	Preparation for broad generic entry
First major generic entry	November 30, 2011	Ranbaxy generic launch
Broad generic market	2012 onward	Rapid erosion of branded pricing and share

Pfizer reported LIPITOR revenue of approximately $9.6 billion in 2011, reflecting the product’s importance immediately before broad generic erosion. [4] Earlier peak-year estimates exceeded $10 billion annually, but current revenue exposure is primarily associated with generic atorvastatin rather than the original branded product.

What is the FDA and Orange Book status of LIPITOR?

LIPITOR was approved under NDA 020702. The product is an FDA-approved small-molecule prescription drug in tablet form. Generic atorvastatin products have been approved through abbreviated new drug applications, generally demonstrating pharmaceutical equivalence and bioequivalence rather than repeating the full clinical development program.

The Orange Book historically listed patents associated with the LIPITOR NDA. The practical significance of those listings has declined as the major listed patents expired and generic manufacturers entered the market. Current diligence should distinguish between:

1. Historical Orange Book listings for LIPITOR.
2. Active patents listed for specific atorvastatin products.
3. Patents covering newly developed formulations or delivery systems.
4. Patent claims that remain enforceable in a particular country.

An ANDA applicant seeking approval before listed patent expiry may file a Paragraph IV certification. The applicant must assert that the patent is invalid, unenforceable, or will not be infringed. Pfizer’s litigation and settlement history with Ranbaxy was central to the timing of generic atorvastatin entry. [2,3]

Which companies challenged LIPITOR patents?

Ranbaxy Laboratories was the most commercially important early challenger. Its Paragraph IV challenge led to litigation and a settlement that permitted generic atorvastatin entry on November 30, 2011, subject to the settlement terms.

Other generic companies entered after the principal barriers weakened or expired. The competitive field has included large generic manufacturers such as Teva, Mylan, Sandoz, Dr. Reddy’s, Apotex, and Watson/Actavis, depending on jurisdiction and product strength.

The exact litigation posture varied by patent, ANDA filer, and dosage strength. A complete current litigation opinion requires a live review of PACER, FDA Orange Book listings, district court dockets, Federal Circuit decisions, and settlement disclosures.

What excipient strategy is most commercially attractive for atorvastatin?

The highest-value strategy is not to copy the LIPITOR excipient list. It is to solve specific formulation or market-access problems.

1. Lactose-free atorvastatin tablets

LIPITOR uses lactose monohydrate. A lactose-free product could target patients with lactose intolerance, manufacturers seeking simplified excipient declarations, or markets where lactose is less desirable for patient acceptability.

Potential replacements include:

• Mannitol
• Anhydrous dibasic calcium phosphate
• Pregelatinized starch
• Spray-dried cellulose systems
• Co-processed mannitol-cellulose excipients

A lactose-free formulation could be filed as a conventional ANDA if it remains pharmaceutically equivalent and bioequivalent. The change would have to satisfy quality, dissolution, stability, and inactive-ingredient requirements.

2. Low-moisture and improved-stability formulations

Atorvastatin formulations can be sensitive to degradation pathways involving moisture, oxidation, light, and pH. A formulation platform using low-moisture excipients, protective packaging, antioxidants, or optimized microenvironmental pH could reduce degradation and improve shelf life.

Commercially relevant tools include:

• Desiccant packaging
• High-barrier blister systems
• Low-moisture fillers
• Antioxidant systems
• Controlled-pH microenvironments
• Nitrogen-protected manufacturing and packaging

The patent opportunity would be stronger if the formulation produced a demonstrated stability or impurity advantage, not merely a different excipient list.

3. Smaller tablets and high-load compression

The 80 mg strength is commercially important for high-risk cardiovascular patients, but tablet size and swallowing burden remain relevant. A high-density, directly compressible excipient system could reduce tablet size or improve mechanical strength without compromising dissolution.

Potential technical claims could address:

• Excipient ratios
• Compression force
• Tablet tensile strength
• Disintegration time
• Dissolution profile
• Moisture content
• Granulation method
• Coating weight

Such claims are more defensible when supported by comparative data against LIPITOR and leading generic atorvastatin products.

4. Orally disintegrating or sprinkle formulations

A pediatric or dysphagia-oriented atorvastatin formulation could support a 505(b)(2) or other regulatory pathway, depending on the product’s design and the extent of reliance on the reference drug.

Potential formats include:

• Orally disintegrating tablets
• Mini-tablets
• Granules for administration with soft food
• Oral suspensions
• Sachets
• Multiparticulates

These products would require careful control of atorvastatin taste, dose uniformity, chemical stability, and food compatibility. The opportunity is greater in populations that have difficulty swallowing conventional film-coated tablets.

What formulation patents could protect an improved atorvastatin product?

A commercially meaningful patent estate would typically combine formulation, process, and use claims.

Claim category	Example protected subject
Composition	Defined excipient ratios and atorvastatin concentration
Solid form	Specific atorvastatin calcium polymorph or crystalline form
Dissolution	Formulation meeting a defined dissolution profile
Stability	Reduced lactone formation or impurity growth
Manufacturing	Wet granulation, dry granulation, roller compaction, or coating process
Packaging	Moisture- and oxygen-control configuration
Dosage form	Orally disintegrating tablet, suspension, granule, or sprinkle product
Method of use	Specific cardiovascular-risk population or dosing regimen
Combination product	Atorvastatin combined with another cardiovascular agent

Method-of-use patents are less central for ordinary generic atorvastatin because the main indications are well established. They may have value for a new patient subgroup, adherence-focused regimen, or combination therapy, but they must avoid claims that are inherently practiced by routine generic use.

How strong is the patent estate for an excipient-based atorvastatin product?

A basic excipient substitution generally has weak patent strength. Replacing lactose with mannitol or changing magnesium stearate levels is often vulnerable to obviousness challenges unless the formulation produces an unexpected technical result.

A stronger estate would require:

1. A specific excipient combination.
2. A defined manufacturing process.
3. A measurable performance advantage.
4. Comparative data against the reference product.
5. Claims that are difficult to design around.
6. Commercial relevance, such as longer shelf life, reduced tablet size, or improved administration.

The most defensible strategy is a layered portfolio:

• Composition-of-matter claims for a novel solid form, where available.
• Formulation claims covering excipient ratios.
• Process claims covering granulation or coating.
• Packaging claims covering stability protection.
• Method-of-use claims for a differentiated patient population.

Because atorvastatin is an established active ingredient, obviousness and written-description risks are material. Patent claims should be supported by robust formulation screening, impurity analysis, dissolution testing, stability data, and human-factor evidence where the product changes administration.

What manufacturing and intellectual-property barriers remain?

The active ingredient is widely available, and ordinary atorvastatin tablets are manufactured by many suppliers. The principal barriers are therefore execution barriers rather than basic molecule access.

Important barriers include:

• Consistent atorvastatin calcium particle-size control.
• Polymorph and solid-form management.
• Low-level impurity control.
• Scale-up of granulation and coating.
• Bioequivalence across strengths.
• Stability under accelerated and long-term conditions.
• Supply reliability for specialty excipients.
• Colorant and coating compliance across jurisdictions.
• Control of excipient variability.
• FDA inspection readiness and data integrity.

A manufacturer with a validated low-moisture process, reliable API sourcing, and strong dissolution control may have a cost advantage even without a broad patent estate.

How does LIPITOR compare with competing statins?

Drug	Active ingredient	Dosage-form opportunity	Patent and regulatory position
LIPITOR	Atorvastatin calcium	Standard tablet, ODT, sprinkle, suspension, combination product	Mature generic market
CRESTOR	Rosuvastatin calcium	Tablets and differentiated delivery systems	Mature generic market, historically later erosion
ZOCOR	Simvastatin	Immediate-release tablet and combination concepts	Mature generic market
PRAVACHOL	Pravastatin sodium	Tablet and liquid opportunities	Mature generic market
LESCOL	Fluvastatin sodium	Capsule or tablet formulation	Mature generic market

Atorvastatin has a large installed prescriber base, broad clinical familiarity, and multiple strengths. That supports commercial opportunities in adherence, dose flexibility, combination products, and low-cost manufacturing. The same scale also creates intense price competition.

Does biosimilar risk apply to LIPITOR?

No. LIPITOR contains atorvastatin, a chemically synthesized small molecule. It is regulated as a conventional small-molecule drug, not as a biologic. Biosimilar competition is therefore not the relevant risk category.

The relevant competitors are:

• ANDA-approved generic atorvastatin products.
• Authorized generics.
• Fixed-dose cardiovascular combinations.
• Other statins.
• Nonstatin lipid-lowering drugs such as ezetimibe and PCSK9 inhibitors.
• Novel oral lipid-lowering agents.

What licensing and partnership opportunities exist?

The most credible licensing opportunities involve differentiated dosage forms or manufacturing platforms rather than rights to ordinary atorvastatin tablets.

Potential partners include:

• Generic pharmaceutical companies with ANDA infrastructure.
• Specialty manufacturers of orally disintegrating tablets.
• Excipient suppliers with co-processed systems.
• Contract development and manufacturing organizations.
• Cardiovascular companies developing fixed-dose combinations.
• Regional manufacturers in emerging markets.

A licensable asset should include more than a formulation concept. Commercial value is higher when the package includes an issued or pending patent family, reproducible pilot-scale data, a defined regulatory pathway, and a clear cost-of-goods advantage.

What generic launch scenarios exist for improved atorvastatin products?

Conventional ANDA launch

A lactose-free or excipient-modified immediate-release tablet may be suitable for an ANDA if it meets pharmaceutical equivalence, bioequivalence, quality, and labeling requirements. This pathway has the lowest regulatory risk but also the weakest differentiation.

505(b)(2) launch

A novel suspension, orally disintegrating product, or other dosage form may support a 505(b)(2) strategy when the product differs materially from the reference drug. The sponsor may obtain a period of regulatory exclusivity for qualifying innovation, although the exact scope depends on the approved product and listed patents.

Combination-product launch

Atorvastatin combinations with ezetimibe, antihypertensive agents, or antiplatelet drugs can address pill burden. Regulatory and patent value depends on the combination, dosing rationale, clinical evidence, and competitive products.

Geographic launch

Outside the United States, opportunities may remain in markets where branded atorvastatin has stronger physician recognition, generic substitution is incomplete, or local manufacturing creates procurement advantages. Patent status must be reviewed separately by country because U.S. expiry does not determine protection in Europe, Japan, China, India, Latin America, or other markets.

Key Takeaways

• LIPITOR is an immediate-release atorvastatin calcium tablet with a conventional excipient system.
• Its core molecule and principal commercial patent barriers have expired, and generic atorvastatin is widely available.
• The strongest excipient opportunities involve lactose-free tablets, improved moisture stability, smaller high-strength tablets, orally disintegrating formats, and sprinkle or suspension products.
• Simple excipient substitution is unlikely to support a strong patent position without unexpected technical results.
• A stronger portfolio combines composition, process, stability, packaging, dosage-form, and selected method-of-use claims.
• LIPITOR has no biosimilar risk because atorvastatin is a small molecule.
• The most practical regulatory routes are an ANDA for a conventional product and a 505(b)(2) pathway for a materially differentiated dosage form.
• Commercial value depends on formulation performance, manufacturing cost, regulatory differentiation, and access to high-volume generic channels.

FAQs

Can a company copy the LIPITOR excipient formulation?

A company may generally develop a pharmaceutically equivalent atorvastatin product, subject to current patent, regulatory, trade-secret, and manufacturing requirements. Exact copying does not provide a commercial advantage and may create unnecessary patent or product-liability exposure.

Is atorvastatin calcium a patentable excipient platform?

The excipient itself is usually not patentable as a known material. Patent value may arise from a novel combination of atorvastatin calcium and excipients, a defined process, a stability result, or a specialized dosage form.

Can a lactose-free atorvastatin product receive FDA approval?

Yes. A lactose-free product may be eligible for approval if it satisfies the applicable FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, labeling, and inactive-ingredient safety.

Are atorvastatin combination tablets protected by formulation patents?

Some combination products may have active patents or regulatory exclusivity, but protection depends on the specific active ingredients, strength ratios, dosage form, jurisdiction, and patent claims. Ordinary atorvastatin tablets do not automatically protect a later combination product.

Does an atorvastatin oral suspension have more commercial value than a standard tablet?

It can, particularly for patients with dysphagia, pediatric use, or administration flexibility. Its value depends on taste masking, chemical stability, dose uniformity, packaging, bioequivalence or clinical requirements, and the strength of any resulting patent or regulatory exclusivity.

References

1. U.S. Food and Drug Administration. (2023). LIPITOR (atorvastatin calcium) tablets: Prescribing information.
2. Federal Trade Commission. (2008). FTC closes investigation of proposed settlement between Pfizer and Ranbaxy involving generic version of Lipitor.
3. U.S. District Court for the District of Delaware. (2002). Warner-Lambert Company v. Ranbaxy Laboratories Ltd., related atorvastatin patent litigation records.
4. Pfizer Inc. (2011). 2011 annual report.